Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Zika Virus: Testing for Austria vaccine begins

logo Themis © Themis

The clinical study will focus on identifying the most suitable doses of the vaccine candidate in regard to immunogenicity, safety, and tolerability. Therefore up to 48 healthy volunteers will participate in the study and three different treatment regimens will be compared with a placebo treatment. One treatment group will receive one injection of high dose vaccine, the other two groups will receive two shots of either high dose or low dose vaccine. Results of all groups are expected within the next six months. The study will be conducted at the "Department of Clinical Pharmacology" and the "Institute of Specific Prophylaxis and Tropical Medicine" at the Medical University of Vienna, Austria.

Zika is a viral infection transmitted by mosquitoes. It originates in Asia and parts of Africa but the increase in global traveling and rising temperatures may cause it to spread into more temperate zones. Recently, the virus spread across the Pacific Ocean to the Americas, leading to the 2015/16 virus epidemic.

About Themis

Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected measles virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for all current vaccine candidates of the Vienna-based company.
www.themisbio.com

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Research and Found Your Company in Austria

    29.01.2020 / 16:30 - 18:00, Zurich, Switzerland

  • New Year's Reception

    29.01.2020 / 18:00, Zurich, Switzerland

Austria Map

Find the perfect location for your company

As a gaming machine and gaming software company, we particularly profit from the high level of education and innovative strength of Austria as a business location. We also value the strong loyalty and commitment of our local employees.

IGT Austria GmbH

igt
More testimonials

news from the business location Austria

New ultrasound method against Alzheimer’s

In neurological diseases such as Alzheimer's disease, Parkinson's disease or multiple sclerosis, brain neurons are constantly being lost.

The new research allowance in Germany – in competition with the Austrian research tax credit?

Companies carrying out research and development in Austria have the possibility to apply for research funding, namely the so-called research tax credit. In an international comparison, the Austrian research tax credit is a recipe for success and is designed to showcase and enhance the attractiveness of Austria as a research location. The successive increase in the research tax credit from the original level of three percent in 2002 to 14 percent at present has made a massive contribution to this success.

More news All blog posts